Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
100%(4 trials)

Phase Distribution

Ph phase_4
1
20%
Ph phase_3
3
60%
Ph phase_2
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (20.0%)
Phase 33 (60.0%)
Phase 41 (20.0%)

Trials by Status

completed480%
withdrawn120%

Recent Activity

0 active trials
Showing 5 of 5
withdrawnphase_2

Fingolimod in COVID-19

NCT04280588
completedphase_4

Fingolimod Effect on Cytokine and Chemokine Levels

NCT02373098
completedphase_3

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

NCT00340834
completedphase_3

Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

NCT00662649
completedphase_3

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

NCT00289978

Clinical Trials (5)

Showing 5 of 5 trials
NCT04280588Phase 2

Fingolimod in COVID-19

Withdrawn
NCT02373098Phase 4

Fingolimod Effect on Cytokine and Chemokine Levels

Completed
NCT00340834Phase 3

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Completed
NCT00662649Phase 3

Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Completed
NCT00289978Phase 3

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5